U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07583030) titled 'A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases' on April 24.
Brief Summary: This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)
Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
Progressive Multiple Sclerosis (PMS)
Relapsed/Refractory Myasthenia Gravis(r/r MS)
Intervention:
BIOLOGICAL: LVIVO-TaVec400 product
Each subject will be giv...